Related Experiment Videos
Dependence-related screening positivity among regular stimulant-laxative users with chronic constipation: a
Yo Ishihara1,2,3, Eikichi Ihara2,4, Mitsuru Esaki4
1Department of Palliative Medicine, International University of Health and Welfare Narita Hospital, 852, Hatakeda, Narita, Chiba, 286-8520, Japan.
Background:
Chronic constipation is common, and the appropriate use of stimulant laxatives remains challenging. Although dependence due to habitual stimulant-laxative use is frequently observed, the long-term effects of regular use on dependence and tolerance have not been fully elucidated. This study aimed to characterize the clinical features and substance use-related symptoms associated with stimulant-laxative use in patients with chronic constipation.
Methods:
This multicenter prospective observational study was conducted at three centers and enrolled patients with chronic constipation, including those meeting the Rome IV criteria. Patients were categorized based on stimulant-laxative use into None (N), Short-term/Rescue (SR), and Regular (R), defined as the use of stimulant laxatives ≥ 3 per week for > 1 year. Substance use-related symptoms were assessed using the CAGE-AID questionnaire (≥ 2 point), and self-reported ICD-11 and DSM-5-TR substance use disorder criteria.
Results:
A total of 280 patients were included (N = 197, SR = 51, R = 32). Baseline characteristics did not differ significantly among groups. CAGE-AID positivity was 5.1%, 58.8%, and 90.6% in the N, SR, and R groups, respectively. ICD-11 criteria were markedly higher in the R group (65.6%) compared with the N (0%) and SR (11.8%) groups. DSM-5-TR criteria showed a similar pattern (0%, 15.7%, and 65.6%, respectively). The R group consistently demonstrated higher positive screening rates across all tools.
Conclusions:
Long-term stimulant-laxative use is associated with increased substance use-related symptoms and features suggestive of habituation in patients with chronic constipation.
Trial Registration:
The study was registered in the University Hospital Medical Information Network (UMIN000051617) on July 15, 2023.
Related Concept Videos
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This makes...
Drugs for Treatment of Constipation-Predominant IBS
Drugs Affecting GI Tract Motility: Other Laxatives
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Assessment of the Rectum and Anus
Rectal Inspection
Begin by inspecting the perianal and anal areas for color, texture, rashes,...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists